Physician profile
Robin Karasek
NPI 1558823740
$2,304.65
in general payments reported to CMS, 2019-2025
20 companies · $696 in 2025
The $696 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.93 · 2023: $802 · 2024: $710 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.73 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $390.37 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Shield Therapeutics INC | $306.22 | 2023-2025 | Accrufer |
| Abbvie INC. | $235.62 | 2023-2025 | |
| Lilly USA, LLC | $206.29 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $183.22 | 2023-2025 | Repatha, Repatha, Otezla |
| Astellas Pharma US INC | $143.77 | 2023-2024 | Veozah |
| Glaxosmithkline, LLC. | $112.11 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $101.73 | 2023-2025 | Airsupra, Fasenra |
| Polarityte, INC. | $96.93 | 2019 | |
| Pfizer INC. | $96.80 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.22 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $86.29 | 2023-2024 | |
| Exact Sciences Corporation | $67.26 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $47.72 | 2023-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $37.61 | 2023 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $22.88 | 2023 | |
| Lifescan, INC. | $21.70 | 2023 | |
| Phadia US INC. | $19.72 | 2024 | Immunocap |
| Philips North America LLC | $17.80 | 2024 | (Ck6) Holter |
| Abiomed | $17.39 | 2024 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Karasek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.